TW202320762A - 氘化化合物 - Google Patents

氘化化合物 Download PDF

Info

Publication number
TW202320762A
TW202320762A TW111129796A TW111129796A TW202320762A TW 202320762 A TW202320762 A TW 202320762A TW 111129796 A TW111129796 A TW 111129796A TW 111129796 A TW111129796 A TW 111129796A TW 202320762 A TW202320762 A TW 202320762A
Authority
TW
Taiwan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
compound according
mmol
Prior art date
Application number
TW111129796A
Other languages
English (en)
Chinese (zh)
Inventor
舒楚天
勁 田
Original Assignee
香港商禮邦醫藥（香港）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港商禮邦醫藥（香港）有限公司 filed Critical 香港商禮邦醫藥（香港）有限公司
Publication of TW202320762A publication Critical patent/TW202320762A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW111129796A 2021-08-13 2022-08-09 氘化化合物 TW202320762A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2021112521 2021-08-13
WOPCT/CN2021/112521 2021-08-13
CN2022106648 2022-07-20
WOPCT/CN2022/106648 2022-07-20

Publications (1)

Publication Number Publication Date
TW202320762A true TW202320762A (zh) 2023-06-01

Family

ID=85199822

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111129796A TW202320762A (zh) 2021-08-13 2022-08-09 氘化化合物

Country Status (11)

Country Link
US (1) US20240270731A1 (https=)
EP (1) EP4384507A4 (https=)
JP (1) JP2024532807A (https=)
KR (1) KR20240047401A (https=)
CN (1) CN116848095B (https=)
AR (1) AR126778A1 (https=)
CA (1) CA3227149A1 (https=)
IL (1) IL310176A (https=)
MX (1) MX2024001889A (https=)
TW (1) TW202320762A (https=)
WO (1) WO2023016440A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐
TW202547458A (zh) * 2024-03-26 2025-12-16 香港商禮邦醫藥（香港）有限公司 用於治療體染色體顯性多囊性腎病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60211891T2 (de) * 2001-05-15 2007-05-24 F. Hoffmann-La Roche Ag Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
JP7618384B2 (ja) * 2017-02-21 2025-01-21 ジェンフィ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
CN109265380A (zh) * 2017-10-18 2019-01-25 深圳市塔吉瑞生物医药有限公司 取代的丙-2-烯-1-酮化合物及其药物组合物
WO2020156683A1 (en) * 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
CN112209896B (zh) * 2019-07-10 2023-05-16 苏州泽璟生物制药股份有限公司 噻唑烷二酮衍生物以及包含其的药物组合物
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐

Also Published As

Publication number Publication date
CA3227149A1 (en) 2023-02-16
AR126778A1 (es) 2023-11-15
US20240270731A1 (en) 2024-08-15
EP4384507A4 (en) 2025-06-18
CN116848095A (zh) 2023-10-03
EP4384507A1 (en) 2024-06-19
JP2024532807A (ja) 2024-09-10
WO2023016440A1 (en) 2023-02-16
AU2022327461A1 (en) 2024-02-01
KR20240047401A (ko) 2024-04-12
CN116848095B (zh) 2024-05-24
MX2024001889A (es) 2024-02-29
IL310176A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
CN111138301B (zh) 联苯类化合物、其中间体、制备方法、药物组合物及应用
AU781141B2 (en) Novel use of phenylheteroalkylamine derivatives
ES2261202T3 (es) Derivados de acido de triarilo como ligandos para el receptor ppar.
JP6121339B2 (ja) 芳香環化合物
JP2025131575A (ja) Ｍａｓ関連ｇタンパク質受容体ｘ４のモジュレーターおよび関連製品ならびに方法
JP7278273B2 (ja) アクチビン受容体様キナーゼの阻害剤としての置換ピロロピリジン
SK15532001A3 (sk) Deriváty kyselín s dvoma arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
EP2744807A1 (en) Lysophosphatidic acid receptor antagonists
JP7233059B2 (ja) 結核に対する薬剤と組み合わせた環融合型チアゾリノ２－ピリドン
CN103333134B (zh) 2-(3-氰基-4-烷氧基)苯基-4-取代噻唑-5-甲酸类化合物、组合物及其制备方法和用途
TW202320762A (zh) 氘化化合物
AU2015207690B2 (en) Substituted bicyclic heteroaryl compounds as RXR agonists
JP2025532510A (ja) アルファ－１アンチトリプシンの調節剤
CA2891710C (en) Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
US8772304B2 (en) Benzimidazole inhibitors of leukotriene production
JP2022542613A (ja) ヒトａｔｇｌの阻害剤
TW202434578A (zh) 氘代化合物的晶型或鹽
AU2022327461B2 (en) Deuterated compounds
JP2007503431A (ja) 糖尿病及び脂質障害の治療のためのクロマンカルボン酸誘導体
HK40092869A (zh) 氘代化合物
HK40092869B (zh) 氘代化合物
JP2008512384A (ja) Ｐｐａｒアゴニスト活性を有するフィブラート化合物
HK40052029A (en) Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
JP2008506685A (ja) スルファミド誘導体及びそれを含有する脂肪代謝促進用医学組成物